Pyrotinib Maleate, CDK4/6 Inhibitor and Letrozole in Combination for Stage II-III TPBC: a Phase II Trial
Status:
Recruiting
Trial end date:
2026-12-30
Target enrollment:
Participant gender:
Summary
The emergence of CDK4/6 inhibitors has brought hope to breast cancer patients resistant to
endocrine therapy. In the mouse model, pyrotinib maleate combined with CDK4/6 inhibitor
exhibits higher anti-tumor activity than any anti-tumor drug alone. Moreover, the toxicity of
the combined therapy does not increase compared with monotherapy. This provides a good
preclinical model for the treatment of breast cancer by pyrotinib maleate combined with
CDK4/6 inhibitor. Based on above, it is hypothesized that pyrotinib maleate, CDK4/6 inhibitor
SHR6390 and aromatase inhibitor letrozole in combination can provide a better neoadjuvant
strategy for stage II-III triple-positive breast cancer.